Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702196 | 0.94 | ALDH1A1 (0.57) | SMN1; SMN2LMNANPC1RAB9APOLB | |
| SCHEMBL28218368 | 0.88 | MAPT (0.58) | SMN1; SMN2LMNANPC1RAB9APOLB | |
| SCHEMBL1782973 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNANPC1RAB9APOLB | |
| SCHEMBL30914249 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL25775259 | 0.83 | HDAC1 (0.55) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL30100249 | 0.83 | HDAC1 (0.55) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL29227032 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL30858825 | 0.83 | HDAC6 (0.68) | SMN1; SMN2LMNANPC1RAB9APOLB | |
| SCHEMBL28167267 | 0.82 | MAPT (0.61) | SMN1; SMN2LMNANPC1RAB9APOLB | |
| SCHEMBL8213846 | 0.82 | NPC1 (0.66) | SMN1; SMN2LMNANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | SMN1; SMN2 166/4885LMNA 1017/4885NPC1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.